| USP | | accelerator-produced radionuclide; bounds to blood protein |
| Mertiatide | | pertechnetate localizes in the thyroid by this method |
| in vivo | | method of analyzing, recording, and measuring radiation |
| IND | | sits retroperitoneum |
| New Drug Application | | murine origin |
| CSF | | prepared from stannous reduced Tc99m and betiatide |
| MAA | | used to image the lungs |
| impurity | | by mouth |
| skeletal system | | occurs outside the body (e.g. RBC labeling) |
| Thallium | | has set a limit of 10ug Al 3 |
| TLC | | NaTcO4 and reduced technetium |
| Sulfur Colloid | | half life of 73.1 hours |
| thyroid | | group physical data for penetrating and nonpenetrating radiation |
| Dosimetry | | isonitrile compound |
| MIRD | | lung agent used during ventilation |
| oral | | choroid plexus is found here |
| Xe133 | | lidofenin, disofenin, disofenin are used in what |
| ion trapping | | requires boiling |
| radionuclidic purity | | quantifies different radiochemical states |
| monoclonal | | final approval procedure required by the FDA |
| HIDA SCAN | | uses iodine |
| Sestamibi | | assess drug's safety before use |
| brain | | choroid plexus produces |
| Gallium | | MDP,HDP are used to image this |
| in vitro | | occurs inside the body (e.g. RBC tagging) |
| kidney | | 0.15 uCi of Mo99/ 1mCi Tc99m |
